Quince rises as FDA lifts partial hold on late-stage study for lead drug

IRulya Therapeutics

28/09/2023 21:29

** Shares of drug developer Quince Therapeutics  QNCX.O 
rise 19% to $1.37 after the bell
    ** Company says U.S. FDA has lifted partial clinical hold on
late-stage study for its lead drug, EryDex
    ** The drug is being studied for the treatment of
Ataxia-Telangiectasia, a rare, fatal pediatric neurological
disease
    ** QNCX gained access to the drug with the acquisition of
privately held EryDel SpA
    ** Patient enrollment for study to begin as soon as Q2 2024
- company
    ** Stock up ~84% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))